Cetrelimab
Monoclonal antibody
Evidence outlook · registrational
Bladder Cancer: topline reported 2024-09-09
No completed mid-stage readout is on record. The sponsor reported topline results on 2024-09-09 (SunRISe-2 stopped for futility). The announcement is listed under Regulatory events. An earlier registrational trial (SunRISe-2 (NCT04658862)) missed its primary endpoint; the trial rows below carry the recorded results.
Latest reported trial: SunRISe-2 (NCT04658862) · Phase 3 · missed primary endpoint · grade pending
Also in development:Non-Small Cell Lung Cancer · Phase 1/2
Development in Multiple Myeloma stopped for reasons the sponsor has not stated. Development continues in another indication. Source
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
SunRISe-3 NCT05714202 · Bladder Cancer Registry: NCT05714202 | 3 | Event-free Survival (EFS) (Up to 5 years 2 months) 2029-09-18 | In progress: results expected 18 Sept 2029 | not yet graded | link ↗ |
View 1 more trial
SunRISe-2 NCT04658862 · Urinary Bladder Neoplasms SunRISe-2 was a randomized, open-label Phase 3 trial in 518 patients with muscle-invasive bladder cancer that compared TAR-200 (INLEXZO) plus cetrelimab with concurrent chemoradiotherapy. The primary endpoint was bladder-intact event-free survival. In September 2024 the independent data monitoring committee recommended stopping the study because prespecified futility criteria were met. At the July 2025 data cutoff, the combination did not improve bladder-intact event-free survival, with 12-month rates of 65.5% against 79.9% for chemoradiotherapy, so the primary endpoint was missed. Cetrelimab was given only as part of the combination, so the trial does not isolate its own effect. The figures come from the sponsor's medical information page (Johnson & Johnson), which summarizes a 2026 presentation by Necchi et al. Result from the sponsor's medical information page summarizing a 2026 conference presentation; no peer-reviewed publication or posted registry results were found. Registry: NCT04658862 | 3 | Time from Randomization to the First Bladder Intact Event-free Survival (BI-EFS) event (Up to 8 years) 2026-12-30 | Bladder-intact EFS, TAR-200 (INLEXZO) plus cetrelimab vs chemoradiotherapy: not improved. 12-month BI-EFS 65.5% (95% CI 57.9 to 72.1) vs 79.9% (95% CI 72.3 to 85.6); study stopped for futility. No hazard ratio reported. | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (2)
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (3)
What this study did
What this study did
What this study did
Phase 1 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other PD-1 drugs
Cemiplimab, Dostarlimab, Nivolumab, Opdivo Qvantig, Pembrolizumab and 21 more. Compare all 27 PD-1 drugs
This mechanism is crowded: 26 other tracked programmes target it, 10 of them ahead of this one.
This drug's own stage for Bladder Cancer: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Cetrelimab: this drug | Phase 3 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Durvalumab | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Enfortumab Vedotin | Approved | Antibody–drug conjugate | Nectin-4 | Partial signal | NCT03474107: Overall Survival (OS) (From randomization until the analysis cut-off date of 15-Jul-2020 (median OS follow-up was 11.10 months)): Enfortumab Vedotin 1.25 mg/kg 12.88 months (95% CI 10.58 to 15.21) | Chemotherapy 8.97 months (95% CI 8.05 to 10.74) NCT03219333: Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) (Cohort 1: median follow-up time: 10.15 months (range 0.49, 16.46); Cohort 2: median follow up time: 13.4 months (range 0.33 to 29.27)): Enfortumab Vedotin - Cohort 1 44 Percentage of Participants (95% CI 35.1 to 53.2) | Enfortumab Vedotin - Cohort 2 51.7 Percentage of Participants (95% CI 40.8 to 62.4) | |
| Nogapendekin Alfa Inbakicept (Anktiva) | Approved | Protein / enzyme therapeutic | IL-15 superagonist | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex) | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs) | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Iparomlimab (QL1604) | Phase 3(overall) | Monoclonal antibody | PD-1 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Sacituzumab Tirumotecan | Phase 3 | Antibody–drug conjugate | TROP2 | not yet graded | No reviewed efficacy summary in this indication | |
| Tremelimumab | Phase 3 | Monoclonal antibody | CTLA-4 | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-3045 | Phase 2(overall) | Undisclosed | PD-1 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Visugromab | Phase 2 | Monoclonal antibody | GDF-15 | Weak signal | NCT06059547: Two primary endpoints, no significance test reported (exploratory). Pathologic complete response: 33.3% nivolumab + visugromab (n=15 evaluable) vs 7.1% nivolumab + placebo (n=14 evaluable). Objective response by RECIST 1.1: 60.0% vs 14.3%. Major pathologic response (secondary): 66.7% vs 21.4%. | |
| MK-3120 | Phase 1/2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-2005 | Phase 1/2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| Bmab1700 | Phase 1(overall) | Monoclonal antibody | PD-1 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Tuvutromstat | Phase 1 | Small molecule | MAT2A | not yet graded | No reviewed efficacy summary in this indication | |
| Avipendekin Pegol | —(overall) | Cytokine | IL-15 receptor | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
9 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(10 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Cetrelimab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
2027 (5)
January 2027 (1)
What to watch
April 2027 (1)
What to watch
June 2027 (1)
What to watch
August 2027 (1)
What to watch
December 2027 (1)
What to watch
2028 (3)
January 2028 (1)
2029 (1)
September 2029 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent